LLY

1,040.03

+0.29%↑

JNJ

243.3

-0.53%↓

ABBV

231.41

+1.75%↑

NVS

162.81

+1.21%↑

MRK

121.33

+1.83%↑

LLY

1,040.03

+0.29%↑

JNJ

243.3

-0.53%↓

ABBV

231.41

+1.75%↑

NVS

162.81

+1.21%↑

MRK

121.33

+1.83%↑

LLY

1,040.03

+0.29%↑

JNJ

243.3

-0.53%↓

ABBV

231.41

+1.75%↑

NVS

162.81

+1.21%↑

MRK

121.33

+1.83%↑

LLY

1,040.03

+0.29%↑

JNJ

243.3

-0.53%↓

ABBV

231.41

+1.75%↑

NVS

162.81

+1.21%↑

MRK

121.33

+1.83%↑

LLY

1,040.03

+0.29%↑

JNJ

243.3

-0.53%↓

ABBV

231.41

+1.75%↑

NVS

162.81

+1.21%↑

MRK

121.33

+1.83%↑

Strona główna・Stock List・Puma Biotechnology Inc

Puma Biotechnology Inc

Closed

SectorHealthcare

6.82 0.15

Buy Sell

Overview

Share price change

24h

Current

Min

6.74

Max

6.83

Key metrics
By Trading Economics
Income	3M 8.8M
Sales	2M 54M
P/E Sector Avg	9.297 121.746
Profit margin	16.235
Employees	172
EBITDA	2.7M 13M

Dividends
By Dow Jones
Next Earnings	26 lut 2026

Market Stats
By TradingEconomics
Market Cap	93M 347M
Previous open	6.67
Previous close	6.82

News Sentiment

By Acuity

50%

144 / 351 Ranking in Healthcare

Technical Score

By Trading Central

Confidence

Weak Bullish Evidence

3.07 / 3.075 Support & Resistance

Puma Biotechnology Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

13 lut 2026, 16:32 UTC

Earnings

Enbridge, TC Energy Investing in Opportunities to Tap Rising Energy Demand, Boom in Data Centers -- Update

14 lut 2026, 22:02 UTC

Earnings

Looking for Dividends? Consider Europe. -- Barrons.com

14 lut 2026, 09:20 UTC

Market Talk

Basic Materials Roundup: Market Talk

13 lut 2026, 21:57 UTC

Earnings

Stocks Rise on Softer Inflation Data, but AI Jitters Trigger Worst Week Since November -- WSJ

13 lut 2026, 21:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

13 lut 2026, 21:20 UTC

Earnings

Applied Materials, Rivian, Moderna, Arista, Fastly, Coinbase, Robinhood, DraftKings, and More Stock Market Movers -- Barrons.com

13 lut 2026, 21:05 UTC

Acquisitions, Mergers, Takeovers

Constellation Software: Lumine Group Completes Acquisition of Synchronoss Technologies >CSU.T SNCR

13 lut 2026, 20:45 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

13 lut 2026, 20:45 UTC

Market Talk

Dollar Pares Down Early Losses -- Market Talk

13 lut 2026, 20:39 UTC

Market Talk

Potential for Mild Winter Ahead Sinks Natural Gas for Week -- Market Talk

13 lut 2026, 20:28 UTC

Market Talk

Oil Settles Week Lower -- Market Talk

13 lut 2026, 19:51 UTC

Earnings

These Stocks Are Today's Movers: Applied Materials, Rivian, Moderna, Arista, Fastly, Coinbase, Robinhood, DraftKings, and More -- Barrons.com

13 lut 2026, 19:32 UTC

Market Talk

Gold and Silver Climb to Finish Week In Positive Territory -- Market Talk

13 lut 2026, 19:32 UTC

Market Talk

Gold and Silver Climb to Finish Week In Positive Territory -- Market Talk

13 lut 2026, 19:29 UTC

Earnings

Big Tech's Spending Spree Could Limit Buybacks and Dividends -- Barrons.com

13 lut 2026, 18:18 UTC

Acquisitions, Mergers, Takeovers

Exxon, Walmart and 9 Other Stocks That Are Soaring Because Cash Is King Again -- Barrons.com

13 lut 2026, 17:52 UTC

Earnings

Pinterest's Earnings Give More Proof of Meta Platform's Dominance -- Barrons.com

13 lut 2026, 17:16 UTC

Earnings

These Stocks Are Today's Movers: Applied Materials, Rivian, Moderna, Arista, Fastly, Coinbase, Robinhood, DraftKings, and More -- Barrons.com

13 lut 2026, 17:10 UTC

Acquisitions, Mergers, Takeovers

Vibe-Coding in Gas Town? A Guide to the Software Selloff With 4 Sexy Stock Picks. -- Barrons.com

13 lut 2026, 16:59 UTC

Earnings

AppLovin Stock Stabilizes After Selloff. Its Biggest Critic Waves the White Flag. -- Barrons.com

13 lut 2026, 16:39 UTC

Acquisitions, Mergers, Takeovers

Berkshire Might Have Sold More Apple, Bank of America Stock in Fourth Quarter -- Barrons.com

13 lut 2026, 16:11 UTC

Earnings

Nvidia Stock Wobbles. The Focus Is Turning to Earnings. -- Barrons.com

13 lut 2026, 16:07 UTC

Market Talk

Hungarian Forint Could Rise Further -- Market Talk

13 lut 2026, 15:54 UTC

Earnings

Detroit Automakers Take $50 Billion Hit as EV Bubble Bursts -- WSJ

13 lut 2026, 15:26 UTC

Market Talk

Indian Imports of Saudi Crude Hit Highest Since 2022 -- Market Talk

13 lut 2026, 15:01 UTC

Earnings

These Stocks Are Today's Movers: Applied Materials, Rivian, Moderna, Steel Dynamics, Coinbase, DraftKings, Tri Pointe Homes, and More -- Barrons.com

13 lut 2026, 15:00 UTC

Earnings

Expedia Falls, but Airbnb Rises. Why Online Travel Stocks Face a Tough Year. -- Barrons.com

13 lut 2026, 14:50 UTC

Market Talk

Oil Moves Lower As Market Weighs Geopolitical Risk -- Market Talk

13 lut 2026, 14:44 UTC

Earnings

Arista Networks Stock Climbs. Why It Is Outshining Cisco. -- Barrons.com

13 lut 2026, 14:22 UTC

Market Talk

Earnings

Global Energy Roundup: Market Talk

Peer Comparison

Price change

Puma Biotechnology Inc Forecast

Rating Consensus

By TipRanks

0 ratings

Buy

Hold

Sell

Based on 0 analysts giving stock ratings to Puma Biotechnology Inc - Dist in the past 3 months.

Technical Score

By Trading Central

3.07 / 3.075Support & Resistance

Recent bullish events outweigh bearish events.

Sentiment

By Acuity

144 / 351 Ranking in Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Puma Biotechnology Inc

Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine. It also develops alisertib, a small molecule inhibitor of aurora kinase A for the treatment of hormone receptor positive breast cancer, triple negative breast cancer, small cell lung cancer, and head and neck cancer. The company sells its products through specialty pharmacy and distributor networks. It has license agreements with Pfizer Inc. for the development, manufacture, and commercialization of neratinib (oral), neratinib (intravenous), PB357, and related compounds; and Takeda Pharmaceutical Company Limited for the research, development, and commercialization of alisertib, as well as sub-license agreements with Specialised Therapeutics Asia Pte Ltd., Medison Pharma Ltd., Pint Pharma International SA, Knight Therapeutics, Inc., Pierre Fabre Medicament SAS, and Bixink Therapeutics Co., Ltd. The company was founded in 2010 and is headquartered in Los Angeles, California.